Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma ) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes

J Biol Chem. 2002 Nov 29;277(48):46226-32. doi: 10.1074/jbc.M207776200. Epub 2002 Sep 20.

Abstract

We demonstrate that exposure of post-confluent 3T3-L1 preadipocytes to insulin, isobutylmethylxanthine (MIX), dexamethasone (DEX), and fetal bovine serum induces a rapid but transient activation of MEK1 as indicated by extensive phosphorylation of ERK1 and ERK2 during the initial 2 h of adipogenesis. Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2). Treating the preadipocytes with troglitazone, a potent PPARgamma ligand, could circumvent the inhibition of adipogenic gene expression by U0126. Fibroblast growth factor-2 (FGF-2), in the presence of dexamethasone, isobutylmethylxanthine, and insulin, induces a prolonged activation of the MEK/ERK signaling pathway, which lasts for at least 12 h post-induction, and this activity is less sensitive to the MEK inhibitors. Consequently, preadipocytes treated with U0126 in the presence of fibroblast growth factor-2 (FGF-2) express normal post-induction levels of MEK activity, and, in so doing, are capable of undergoing adipogenesis. We further show that activation of MEK1 significantly enhances the transactivation of the C/EBPalpha minimal promoter during the early phase of the differentiation process. Our results suggest that activation of the MEK/ERK signaling pathway during the initial 12 h of adipogenesis enhances the activity of factors that regulate both C/EBPalpha and PPARgamma expression.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • 3T3 Cells
  • Adipocytes / cytology
  • Adipocytes / metabolism*
  • Animals
  • Butadienes / pharmacology
  • CCAAT-Enhancer-Binding Protein-alpha / genetics*
  • Cell Differentiation*
  • Chromans / pharmacology
  • Dexamethasone / pharmacology
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Gene Expression Regulation* / drug effects
  • Insulin / pharmacology
  • MAP Kinase Kinase 1
  • Mice
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase Kinases / metabolism*
  • Mitogen-Activated Protein Kinases / metabolism*
  • Nitriles / pharmacology
  • Phosphorylation
  • Promoter Regions, Genetic
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / metabolism*
  • Receptors, Cytoplasmic and Nuclear / genetics*
  • Signal Transduction*
  • Thiazoles / pharmacology
  • Thiazolidinediones*
  • Transcription Factors / genetics*
  • Troglitazone

Substances

  • Butadienes
  • CCAAT-Enhancer-Binding Protein-alpha
  • Chromans
  • Insulin
  • Nitriles
  • Receptors, Cytoplasmic and Nuclear
  • Thiazoles
  • Thiazolidinediones
  • Transcription Factors
  • U 0126
  • Dexamethasone
  • Protein Serine-Threonine Kinases
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase 1
  • Map2k1 protein, mouse
  • Mitogen-Activated Protein Kinase Kinases
  • Troglitazone
  • 1-Methyl-3-isobutylxanthine